Savara：市场可能高估了其FDA风险
· seekingalpha.com
Savara (SVRA) 被评级为投机性买入，当前价格4.72美元，12个月目标价7美元，预期将于11月22日迎来关键的FDA决定。
Eljaye W. Tellis is a medicinal chemistry Ph.D. candidate and biotech investor. He covers biotechnology and healthcare equities, applying a therapeutic discover...